Expand ORIC Menu
ORIC MENU

ORIC Latest Press Releases

-- April 14, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC Globe Newswire 5:01 PM

-- April 6, 2026 --

ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses Globe Newswire 8:06 AM

-- April 3, 2026 --

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- March 31, 2026 --

ORIC Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile Globe Newswire 4:05 PM

-- March 27, 2026 --

ORIC Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC Globe Newswire 8:30 AM

-- March 17, 2026 --

ORIC Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting Globe Newswire 5:11 PM

-- March 6, 2026 --

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- February 23, 2026 --

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates Globe Newswire 4:05 PM

-- February 6, 2026 --

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- February 5, 2026 --

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences Globe Newswire 4:01 PM

-- January 12, 2026 --

ORIC Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones Globe Newswire 8:30 AM

-- January 6, 2026 --

ORIC Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 4:05 PM

-- December 5, 2025 --

ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025 Globe Newswire 8:00 PM
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM
ORIC Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025 Globe Newswire 1:00 AM

-- December 4, 2025 --

ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025 Globe Newswire 9:45 PM

-- December 3, 2025 --

ORIC Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025 Globe Newswire 4:01 PM

-- December 1, 2025 --

ORIC Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025 Globe Newswire 8:00 AM

-- November 24, 2025 --

ORIC Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference Globe Newswire 4:05 PM
Market Data Delayed 15 Minutes